WO2003060111A3 - Cancer-specific mutants of b-raf genes and uses thereof - Google Patents

Cancer-specific mutants of b-raf genes and uses thereof Download PDF

Info

Publication number
WO2003060111A3
WO2003060111A3 PCT/GB2002/005921 GB0205921W WO03060111A3 WO 2003060111 A3 WO2003060111 A3 WO 2003060111A3 GB 0205921 W GB0205921 W GB 0205921W WO 03060111 A3 WO03060111 A3 WO 03060111A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
specific mutants
mutations
raf genes
raf
Prior art date
Application number
PCT/GB2002/005921
Other languages
French (fr)
Other versions
WO2003060111A2 (en
Inventor
Mike Stratton
Andy Futreal
Richard Wooster
Richard Malcolm Marais
Chris Marshall
Original Assignee
Catalyst Biomedica Ltd
Mike Stratton
Andy Futreal
Richard Wooster
Richard Malcolm Marais
Chris Marshall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biomedica Ltd, Mike Stratton, Andy Futreal, Richard Wooster, Richard Malcolm Marais, Chris Marshall filed Critical Catalyst Biomedica Ltd
Priority to AU2002356323A priority Critical patent/AU2002356323A1/en
Publication of WO2003060111A2 publication Critical patent/WO2003060111A2/en
Publication of WO2003060111A3 publication Critical patent/WO2003060111A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to mutations in B-Raf gene products. The mutations described are identified in human tumours of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and the development of anti-cancer therapeutics.
PCT/GB2002/005921 2001-12-24 2002-12-24 Cancer-specific mutants of b-raf genes and uses thereof WO2003060111A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356323A AU2002356323A1 (en) 2001-12-24 2002-12-24 Cancer-specific mutants of b-raf genes and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34468401P 2001-12-24 2001-12-24
US60/344,684 2001-12-24

Publications (2)

Publication Number Publication Date
WO2003060111A2 WO2003060111A2 (en) 2003-07-24
WO2003060111A3 true WO2003060111A3 (en) 2004-02-26

Family

ID=23351558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005921 WO2003060111A2 (en) 2001-12-24 2002-12-24 Cancer-specific mutants of b-raf genes and uses thereof

Country Status (2)

Country Link
AU (1) AU2002356323A1 (en)
WO (1) WO2003060111A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556713T1 (en) 1999-01-13 2012-05-15 Bayer Healthcare Llc OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diaryl ureas for diseases mediated by pdgfr
BR122016015715B8 (en) 2003-07-23 2021-05-25 Bayer Healthcare Llc pharmaceutical compositions of 4[4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy)-pyridine-2-carboxylic acid methylamide
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 April 1993 (1993-04-27), SITHANANDAM, G. ET AL.: "Human B-raf mRNA, complete cds", XP002249539, retrieved from M95712 accession no. US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, M Database accession no. gi:179532 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 9 April 1996 (1996-04-09), IKAWA, S. ET AL.: "Human B-raf oncogene mRNA, 3' end", XP002249540, retrieved from M21001 accession no. US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, M Database accession no. gi:179534 *
MACNICOL M C ET AL: "Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 FEB 2000, vol. 275, no. 6, 11 February 2000 (2000-02-11), pages 3803 - 3809, XP002249537, ISSN: 0021-9258 *
OKADA TOMOYO ET AL: "The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases.", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 9, 1999, pages 6057 - 6064, XP002249538, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
WO2003060111A2 (en) 2003-07-24
AU2002356323A1 (en) 2003-07-30
AU2002356323A8 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
WO2003056036A3 (en) Genes
EP2295604A3 (en) Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
EP2502628A3 (en) Polynucleotides and polypeptide sequences involved in cancer
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2008033393A3 (en) Isolation, expansion and uses of tumor stem cells
WO2004071464A8 (en) Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
MXPA03001634A (en) Vaccines.
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2006037462A3 (en) Cancer markers
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2007150044A3 (en) Genetic models for stratification of cancer risk
WO2005000087A3 (en) Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2006045874A3 (en) Use of the slug gene or the replication, transcription or expression products thereof in the identification, diagnosis, prevention or treatment of the spread of cancer and/or the development of metastasis
WO2003060111A3 (en) Cancer-specific mutants of b-raf genes and uses thereof
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
WO2003095977A3 (en) Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
MXPA02011563A (en) Compositions and methods for the therapy and diagnosis of breast cancer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP